Focus: Jazz Pharmaceuticals is a public specialty pharmaceutical company focused on neurology and small-molecule therapeutics, generating $3.8B in annual revenue with significant exposure to cannabinoid and sleep-disorder franchises.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Jazz Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Jazz Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Jazz Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest revenue driver; successor formulation to XYREM with extended LOE through 2041.
Legacy product being transitioned to XYWAV; faces patent cliff by 2033 as patients migrate to newer formulation.
Oncology entry with modest current uptake; LOE protection extends to 2040.
Bispecific HER2-directed antibody in growth phase; represents emerging oncology franchise differentiation.
Oncology biologic addressing asparagine depletion; niche but defensible indication.
Oncology combination therapy with LOE protection through 2033; contributor to AML franchise growth.
Specialized antipsychotic in LOE phase; niche market with declining revenue trajectory.
2 discontinued, 0 duplicate formulations not shown
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront - Pharmaceutical Technology
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront Pharmaceutical Technology
Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition - MedCity News
Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition MedCity News
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn - Eurasia Business News
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn Eurasia Business News
$1.32 Billion for a Molecule: Jazz Pharmaceuticals Bets on Rare-Epilepsy Drug With No Approved Rivals - USA Herald
$1.32 Billion for a Molecule: Jazz Pharmaceuticals Bets on Rare-Epilepsy Drug With No Approved Rivals USA Herald
Jazz Acquires Actio Bioscience | PharmExec - Pharmaceutical Executive
Jazz Acquires Actio Bioscience | PharmExec Pharmaceutical Executive
Jazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal - European Pharmaceutical Review
Jazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal European Pharmaceutical Review
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+1 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo